What's Happening?
ImmunityBio, Inc. has signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG (Tokyo-172 BCG). This agreement aims to address the longstanding BCG shortage in the United States by providing a second
potential source of BCG. The Tokyo strain has shown non-inferior efficacy compared to TICE BCG in a Phase III trial for high-grade non-muscle invasive bladder cancer. ImmunityBio plans to engage with the FDA to pursue approval for this strain, which has been used in Japan for nearly 30 years.
Why It's Important?
The agreement is crucial in addressing the BCG shortage that has affected bladder cancer treatment in the U.S. for over a decade. By securing a reliable supply of the Tokyo strain, ImmunityBio aims to ensure that patients have access to necessary treatments. This development could significantly impact the management of bladder cancer, providing more options for patients and potentially improving outcomes. The collaboration also underscores the importance of international partnerships in overcoming supply chain challenges in healthcare.
What's Next?
ImmunityBio will proceed with regulatory submissions to the FDA for the Tokyo strain of BCG. The company will also continue its partnership with the Serum Institute of India to supply recombinant BCG under an FDA Expanded Access Program. These efforts aim to provide a stable BCG supply for U.S. patients. Further updates on the regulatory pathway and potential approval timelines are expected in future communications from ImmunityBio.
